300630 普利制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.4393.14111.55318.18925.585
总资产报酬率 ROA (%)-1.5671.3865.47310.79517.061
投入资产回报率 ROIC (%)-1.7091.5726.27612.36519.877

边际利润分析
销售毛利率 (%)59.82673.05465.16871.57774.758
营业利润率 (%)-19.9853.67117.85231.02438.516
息税前利润/营业总收入 (%)-15.1499.36319.78833.95039.293
净利润/营业总收入 (%)-15.7176.58718.21727.61134.280

收益指标分析
经营活动净收益/利润总额(%)137.7165.084100.533101.20296.547
价值变动净收益/利润总额(%)-5.5355.884-0.519-0.7590.063
营业外收支净额/利润总额(%)9.09135.998-0.203-0.118-0.784

偿债能力分析
流动比率 (X)1.5651.3821.3781.9481.828
速动比率 (X)1.1781.1641.2021.6961.688
资产负债率 (%)55.08953.77258.06745.4820.333
带息债务/全部投入资本 (%)48.64845.12147.55134.90315.772
股东权益/带息债务 (%)99.069113.499102.593175.795498.001
股东权益/负债合计 (%)81.52585.97172.214119.867200.536
利息保障倍数 (X)-2.2172.58110.03111.45736.521

营运能力分析
应收账款周转天数 (天)494.868311.180214.963175.854140.733
存货周转天数 (天)481.747353.017189.105149.53198.272